Monitor for the actual Form 4 filing to confirm whether the sale was executed. A director/officer sale of this size (50k shares, ~$5.2M) at a $7.2B market cap is notable but not alarming on its own; watch for any pattern of additional insider selling or upcoming catalysts that could explain the timing.
Price Chart
Executive Summary
David Meeker, a director and officer of Rhythm Pharmaceuticals, filed a Form 144 notice of intent to sell 50,000 shares of common stock with an approximate market value of $5.24 million. The shares are to be sold through Morgan Stanley and were acquired via stock option exercise. This is a notable insider sale from a top executive at a $7.2B market cap biotech, though the filing is an advance notice of intent, not a completed transaction.
Key Facts
- David Meeker (Director and Officer) filed Form 144 to sell 50,000 shares.
- Estimated sale value: ~$5,235,500 based on filing date market price.
- Shares to be sold through Morgan Stanley Smith Barney LLC.
- Shares acquired via exercise of stock options on 09/14/2026.
- Filing date: 2026-09-14; proposed sale date also 09/14/2026.
Financial Impact
Proposed sale of 50,000 shares valued at approximately $5.24 million, representing about 0.07% of the company's $7.2B market cap.
Risk Factors
- Insider sale may signal reduced conviction ahead of a potential catalyst or earnings.
- Form 144 is only an intent to sell; the sale may not be executed.
- Stock option exercise and immediate sale could indicate tax planning rather than bearish view.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-009442 |
| Document: 0001950047-26-009442-index.html | 0001950047-26-009442 |
| Document: 0001950047-26-009442.txt | 0001950047-26-009442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access